New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY® (piflufolastat F 18) with the potential for la ...
The FDA has approved a new formulation of an F 18 prostate-specific membrane antigen imaging agent for men with prostate ...
Prostate cancer is the most commonly diagnosed cancer in the UK. But screening is not universal, and charities are divided over whether it should be extended. What do those living with the disease ...
A new drug for prostate cancer, which delivers a precisely targeted dose of radiation to cancer cells, can keep cancer at bay, a phase I trial reports. The ‘search and destroy’ treatment shrank ...
New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY (piflufolastat F 18) with the potential for larger batches and greater pati ...
Genes are only part of your story.
Vietnam Investment Review on MSN
CO PSMA prostate imaging data presented at EAU congress
SYDNEY, March 17, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that ...
First tranche of $15 million expected to close on March 20, 2026; second tranche of up to $15 million available, for up to $30 million in total ...
A redesigned cancer immunotherapy is showing striking early results after decades of disappointment with similar drugs. Researchers engineered a more powerful CD40 agonist antibody and changed how ...
FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.
Penis Botox isn't all that uncommon these days and is chosen for a range of reasons. Tech entrepreneur Bryan Johnson revealed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results